What is Carvykti?
Carvykti is a cell-based medication developed by Johnson & Johnson and Legend Biotech to treat multiple myeloma.
Yanuki
ARTICLE DETAIL
Johnson & Johnson Stock Falters as Cancer Therapy Gets Warning Label | fuboTV Inc. (NYSE:FUBO) Receives Average Rating of "Hold" from Analysts | Apple Stock Outlook: Regulation, Market Trends, and AI | IONQ vs. QBTS: Which Quantum Computing Stock Has the Edge? | Cisco Q2 Earnings: Factors to Watch | Robinhood Markets (NASDAQ:HOOD) Trading Down: What's Happening? | Robinhood (HOOD) Stock Plunges: What's Behind the Dip? | Walmart (WMT) Receives "Moderate Buy" Rating from Analysts | Walmart (NASDAQ:WMT) Shares Up 1.5% - Still a Buy? | Johnson & Johnson Stock Falters as Cancer Therapy Gets Warning Label | fuboTV Inc. (NYSE:FUBO) Receives Average Rating of "Hold" from Analysts | Apple Stock Outlook: Regulation, Market Trends, and AI | IONQ vs. QBTS: Which Quantum Computing Stock Has the Edge? | Cisco Q2 Earnings: Factors to Watch | Robinhood Markets (NASDAQ:HOOD) Trading Down: What's Happening? | Robinhood (HOOD) Stock Plunges: What's Behind the Dip? | Walmart (WMT) Receives "Moderate Buy" Rating from Analysts | Walmart (NASDAQ:WMT) Shares Up 1.5% - Still a Buy?
Stocks / Pharmaceuticals
Johnson & Johnson Stock Falters as Cancer Therapy Gets Warning Label
Johnson & Johnson (JNJ) stock is trending lower following an FDA warning label for its Carvykti cancer therapy, even as the company prepares to release its Q3 earnings report. The FDA sanctioned a warning label to be added to Carvykti, a ce...
Key Insights
- The FDA issued a warning label for Johnson & Johnson’s Carvykti cancer therapy, citing potential fatal impacts on the stomach or intestines.
- Carvykti is a cell-based medication used to treat multiple myeloma, a type of blood cancer.
- Wall Street anticipates Johnson & Johnson to report $23.76 billion in revenue for the upcoming quarter.
- JNJ stock has risen approximately 35% since the start of the year.
In-Depth Analysis
Johnson & Johnson (JNJ) shares are reacting to the FDA’s decision to add a warning label to Carvykti, indicating potential risks of IEC-EC, a bacterial infection affecting the guts.
**Background:** Carvykti received FDA approval in March 2022 and is administered as part of CAR-T therapy, where a patient’s immune cells are modified to attack cancer cells. The FDA approved the warning after reports of patients developing IEC-EC following treatment.
**Stock Performance:** Despite the warning label, JNJ stock has gained about 35% year-to-date. Analysts have a Moderate Buy consensus rating on the stock, with an average price target suggesting a 2% growth potential.
**Takeaway:** Investors should monitor JNJ’s Q3 earnings report to assess the impact of the warning label and overall market conditions on the stock.
FAQ
What is IEC-EC?
IEC-EC is a type of bacterial infection that affects the guts and can cause diarrhea, stomach pain, and fever. It has been reported in some patients treated with Carvykti.
What are analysts expectations for the next quarter?
Wall Street expects Johnson and Johnson to generate $23.76 billion in revenue or about two dollars and 76 cents per share.
Takeaways
- The FDA warning label on Carvykti may influence investor sentiment and the medication’s market performance.
- Keep an eye on Johnson & Johnson’s Q3 earnings to gauge the financial impact of the warning label.
- Analysts remain moderately bullish on JNJ stock, but the situation warrants careful observation.
Discussion
Do you think the FDA warning label will significantly impact JNJ’s stock performance? Share your thoughts in the comments!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.